Outcomes of patients receiving outpatient CAR T-cell therapy
| Outcomes . | Patients with outpatient cell infusion (n = 58) . | All patients intended for outpatient administration (n = 64) . |
|---|---|---|
| ORR∗ | ||
| LYM | 74% (17/23; CR = 12; PR = 5) | 71% (20/28; CR = 13; PR = 7) |
| MM | 75% (24/32; CR = 15; VGPR/PR = 9) | 73% (24/33; CR = 15; VGPR/PR = 9) |
| Median PFS | ||
| LYM | 4.6 mo | 6.2 |
| MM | 12.8 mo | 14.2 |
| Median OS | ||
| LYM | 9.14 mo | 9.14 |
| MM | NR | NR |
| Outcomes . | Patients with outpatient cell infusion (n = 58) . | All patients intended for outpatient administration (n = 64) . |
|---|---|---|
| ORR∗ | ||
| LYM | 74% (17/23; CR = 12; PR = 5) | 71% (20/28; CR = 13; PR = 7) |
| MM | 75% (24/32; CR = 15; VGPR/PR = 9) | 73% (24/33; CR = 15; VGPR/PR = 9) |
| Median PFS | ||
| LYM | 4.6 mo | 6.2 |
| MM | 12.8 mo | 14.2 |
| Median OS | ||
| LYM | 9.14 mo | 9.14 |
| MM | NR | NR |
| CRS∗ (All grade 1-2) . | All patients (n = 58) 79% (46) . | LYM (n = 24) 83% (20) . | MM (n = 33) 76% (25) . | All patients (n = 64) 80% (51) . | LYM (n = 29) 83% (24) . | MM (n = 34) 76% (26) . |
|---|---|---|---|---|---|---|
| ICANS | 28% (16) | 45% (11) | 15% (5) | 31% (20) | 48% (14) | 18% (6) |
| Grade 1-2 | 15% (9) | 8% (5) | 12% (4) | 14% (9) | 17% (5) | 12% (4) |
| Grade 3-4 | 12% (7) | 25% (6) | 3% (1) | 22% (11) | 31% (9) | 6% (2) |
| 30-d admissions∗ | 72% (42) | 87% (21) | 64% (21) | |||
| Days 0-3 | 34% (17) | 37% (9) | 32% (8) | |||
| Days 4-7 | 44% (16) | 46% (11) | 37% (5) | |||
| Days 8-30 | 19% (9) | 4% (1) | 26% (8) | |||
| First dose tocilizumab | ||||||
| Outpatient | 60% (35) | |||||
| Inpatient | 15% (9) | |||||
| CRS∗ (All grade 1-2) . | All patients (n = 58) 79% (46) . | LYM (n = 24) 83% (20) . | MM (n = 33) 76% (25) . | All patients (n = 64) 80% (51) . | LYM (n = 29) 83% (24) . | MM (n = 34) 76% (26) . |
|---|---|---|---|---|---|---|
| ICANS | 28% (16) | 45% (11) | 15% (5) | 31% (20) | 48% (14) | 18% (6) |
| Grade 1-2 | 15% (9) | 8% (5) | 12% (4) | 14% (9) | 17% (5) | 12% (4) |
| Grade 3-4 | 12% (7) | 25% (6) | 3% (1) | 22% (11) | 31% (9) | 6% (2) |
| 30-d admissions∗ | 72% (42) | 87% (21) | 64% (21) | |||
| Days 0-3 | 34% (17) | 37% (9) | 32% (8) | |||
| Days 4-7 | 44% (16) | 46% (11) | 37% (5) | |||
| Days 8-30 | 19% (9) | 4% (1) | 26% (8) | |||
| First dose tocilizumab | ||||||
| Outpatient | 60% (35) | |||||
| Inpatient | 15% (9) | |||||
LYM, lymphoma; VGPR, very good partial response.
The single patient with ALL had grade 1 CRS and was admitted on day 4 due to bacteremia with a CR on day 28.